Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today a new study on the antiviral efficacy of iota-carrageenan (Carragelose) against the original SARS-CoV-2 strain and variants of concern (VOC), including the currently predominant Delta variant, has been published in the International Journal of Molecular Sciences. The peer-reviewed study is the result of a collaboration between virologists at the Friedrich-Alexander-Universität Erlangen- Nürnberg (FAU) and Marinomed as well as scientists from Ulm University Medical Center and the University Hospital Tuebingen who provided the patient-isolates of SARS-CoV-2 VOCs. In short, the study showed that iota-carrageenan was the most effective of the three carrageenans tested. At a concentration as low as 10 ?g/ml, it was able to almost completely block virus replication in Calu-3 human lung cells for all SARS-CoV-2 strains tested, including the highly infectious delta variant.
Marinomed Biotech AG and Luoxin Pharmaceutical Group Stock Co., Ltd. sign agreement on Budesolv to treat allergic rhinitis in Greater China
Korneuburg, Austria, 05 October 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced on 04 October 2021, that it has secured financing in a total amount of up to € 5.4 million via a flexible Convertible Notes Funding Program (CNFP) from the Swiss investment firm Nice & Green S.A. The flexible financing provided by this program enables Marinomed to advance its scientific and clinical programs for its two proprietary assets, the virus blocking Carragelose technology and the Marinosolv platform for the solubilization of pharmaceutical compounds.
Korneuburg, Austria, 25 August 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with
M8 Pharmaceuticals, announced that it has entered into an exclusive licensing agreement with Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms.
M8 Pharmaceuticals, announced that it has entered into an exclusive licensing agreement with Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms.
Korneuburg, Austria, 01 July 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today the topline results for its Phase II clinical trial of Tacrosolv eye drops to treat ocular hay fever symptoms. The placebo-controlled Phase II clinical trial was conducted at the Vienna Challenge Chamber (Austria) to assess safety and efficacy of two different dose of Tacrosolv in a crossover design. The applied doses contained only 2.5 % and 5 % of the dose used in Tacrolimus eye drops that are marketed in Japan for the treatment of vernal conjunctivitis. After one week of treatment, the higher dose resulted in a statistically significant reduction of ocular symptoms in the time period starting 3.5 hours after the challenge (p < 0.05). A comparison of the ocular symptoms on day 1 with day 8 showed a significant reduction of symptoms in the case of Tacrosolv treatment (p < 0.01) without any effect of the placebo treatment. Additionally, nasal symptoms were assessed and showed a significant reduction at day 8 (between 0 to 4 hours after the challenge, p < 0.05). These results indicate the high potential of tacrolimus being an effective treatment of ocular inflammation exemplified by allergic conjunctivitis and other allergic manifestations.
Marinomed Biotech AG, an Austrian science-based biotech company, announced that Carragelose inactivates the new, rapidly spreading variants and SARS-CoV-2 wildtype with similar efficacy in vitro. The company tested the three variants that currently mostly drive the Covid-19 pandemic, namely the so-called British or B.1.1.7, the South-African or B.1.351, and the Brazilian or P1 variant. The data demonstrate that also with increasing prevalence of virus variants, the marketed OTC Carragelose-based lozenges, nasal and throat sprays will continue to effectively contribute to combatting the Covid-19 pandemic.
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today reported strong results for the fiscal year ending 31 December 2020. The company closed the year with an 32 % increase in revenues to € 8.12 m (2019: € 6.14 m). Investments in research and development increased by almost 25 % in 2020 at € 5.94 m (2019: € 4.78 m), of which the largest part is attributable to clinical development. The operating loss (EBIT) of € 5.82 m improved compared to 2019 at € 6.21 m. The total loss for 2020 was reduced to € 6.01 m from € 7.22 m in 2019.